Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

Publisher： Karger

E-ISSN： 1423-0232|79|5-6|423-429

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.5-6, 2011-04, pp. : 423-429

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 239-246

Karger

Access to resources Recommend Favorite

Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 347-352

Karger

Access to resources Recommend Favorite

Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 355-362

Karger

Access to resources Recommend Favorite

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

By Park Keunchil   Goto Koichi  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 561-573

Informa Healthcare

Access to resources Recommend Favorite